Scope and claims map for US Patent 6,362,178 (imidazotriazinone scaffold): breadth, enforceable claim surface, and practical patent-landscape risks for US market entry
US Patent 6,362,178 claims a high-coverage chemical genus centered on “2-phenyl-substituted imidazotriazinone” compounds, with coverage expanded by extensive substituent permutations at multiple positions. The claim set also includes (i) process chemistry, (ii) pharmaceutical compositions using the claimed compounds, and (iii) method-of-use for chronic heart failure and erectile dysfunction (ED). The practical enforcement leverage is strongest against competitors that practice the same core scaffold with any overlapping substituent combinations that read within claim 1’s genus language, plus knock-out protection from product-packaging claims (claim 7) and infringement paths for healthcare indication claims (claim 8) if the competitor labels/administers for those uses.
What does US Patent 6,362,178 claim in plain terms?
Independent claim 1 is the anchor. It is drafted as a structural Markush-style genus: “A compound of the formula (I)” with broad definitions for substituents R1-R4, plus extensive allowance for (a) ring systems (cycloalkyl/aryl/heterocycles), (b) functional groups (sulfonic acid, sulfonamide-like moieties, phosphate/phosphonate esters, etc.), (c) chain interruptions (oxygen in alkyl), and (d) salts/hydrates/N-oxides/structural isomers.
Dependent claims narrow subsets of the same scaffold:
- Claims 2-4: narrower substituent cardinalities and smaller alkyl/aryl options.
- Claim 5: includes specific structures (in your excerpt it ends at “Structure” and does not provide the drawn identities, so the precise structural scope cannot be enumerated from the text provided).
- Claim 6: a specific multi-step synthetic route from intermediates of formulas (II) to (V) and final coupling to amines of formula (VI) using specific reagents/solvents.
- Claim 7: pharmaceuticals containing at least one claimed imidazotriazinone plus excipients.
- Claim 8: method of treating chronic heart failure or ED with administration of a claimed compound.
Claim 1’s practical “read space”
Claim 1 is so parameterized that the set of covered molecules is best treated as:
- a fixed heterocycle core (imidazotriazinone) and a 2-phenyl substitution pattern, and
- a very large set of allowable substituents for R1-R4 (including “hydrogen” as an option and numerous hetero-functional substituents).
That is a genus claim with many degrees of freedom. For infringement, a competitor compound is at high risk if it:
- keeps the imidazotriazinone core and the 2-phenyl substitution, and
- chooses substituents that map onto any overlapping R1/R2/R3/R4 options as defined.
How broad is the claim 1 genus: what substitutions are covered at R1–R4?
R1 and R2: small alkyl allowances (R1), broader alkyl (R2)
From your claim text:
- R1: hydrogen or straight-chain/branched alkyl up to 4 carbons.
- R2: straight-chain alkyl up to 4 carbons.
This makes claim 1 permissive for many analogs that vary small alkyl size and whether R1 is H.
R3 and R4: the biggest breadth driver
R3 and R4 are independently defined, but in the genus they share:
- hydrogen or
- straight-chain/branched alkenyl or alkoxy up to 8 carbons (with optional substitutions), or
- alkyl up to 10 carbons optionally interrupted by oxygen and optionally mono- or polysubstituted with a large menu of groups:
- trifluoromethyl / trifluoromethoxy
- hydroxyl
- halogen
- carboxyl
- benzyloxycarbonyl
- alkoxycarbonyl (up to C6)
- sulfonyl/sulfonic/phosphate-like motifs, including groups of the formulae:
- —SO3H
- —(A)a—NR7R8
- —O—CO—NR7′R8′
- —S(O)b—R9
- —P(O)(OR10)(OR11)
R3/R4 also extend into ring-terminating possibilities via:
- cycloalkyl (C3–C8)
- aryl (C6–C10)
- benzo-fused and heterocycle options with up to 3 heteroatoms from S/N/O
And each ring system can be further substituted with:
- nitro, halogen, SO3H
- small alkyl/alkoxy and carbonyl-like groups
- sulfonamide-like —SO2—NR44R45 motifs
Additional “escape valves” inside claim 1
Claim 1 further includes definitions where:
- R3 or R4 can be “—NR20R21”
- R3 or R4 can be adamantyl
- R3/R4 can be radicals that include further heterocycle formation with the nitrogen atom, yielding 5- to 7-membered saturated or unsaturated heterocycles (up to 3 additional heteroatoms) and these heterocycles can be substituted.
For landscape purposes, these features mean competitors cannot rely on “different side chain architecture” defenses unless their substitutions fall outside the defined radical menus.
What is the enforceable claim surface for pharmaceutical products? (Claim 7)
Claim 7 is a straightforward product claim:
- Pharmaceuticals comprising at least one compound meeting claim 1 plus pharmacologically acceptable formulation agents.
This creates infringement exposure for:
- branded products containing any covered compound,
- generics or licensees that sell the same active or a structural variant still reading on claim 1,
- combination products if they contain at least one compound of claim 1.
In litigation, claim 7 often reduces disputes around dose, because the presence of a covered compound in a marketed dosage form and labeling/packaging for administration can be enough.
What indications are covered by method-of-use claim 8?
Claim 8 is limited to administration for:
- chronic heart failure, or
- erectile dysfunction (ED)
For infringement mapping:
- If a competitor’s product label, REMS/PI, or promotional materials drive use for these indications, the method claim adds a second infringement vector beyond product presence (claim 7).
What does Claim 6 protect: process for making the core scaffold?
Claim 6 is a constrained chemical process claim with:
- conversion of formula (II) intermediates with formula (III) intermediates
- in a two-step reaction:
- first in ethanol
- second in phosphorus oxytrichloride/dichloroethane
- forming formula (IV)
- reaction with chlorosulphonic acid to give formula (V)
- final reaction with amines (VI): HN3R4
- in inert solvents
This structure is typical of enforceable process claims where infringement depends on:
- using the same (or equivalently performing) reaction sequence,
- using the specified reagents and conditions,
- producing the claimed intermediate/formula (V) pathway.
From a design-around perspective, process claim value is high if the market candidate relies on this exact route or a close variant. If the competitor uses a different synthetic logic (different sulfonylation step, different activation chemistry, different solvent/reagent pair), claim 6 risk can drop while compound claims remain.
Dependent claims 2–4: how much narrowing do they actually do?
Based on your excerpt, claims 2–4 mostly:
- reduce maximum alkyl chain lengths (e.g., R1/R2 ≤ C3 in certain dependents),
- constrain substituent variety at side-chain and ring levels,
- swap some allowable substituent sets for smaller alternatives,
- and in places add specific ring examples (piperidinyl/pyridyl/morpholinyl and the like).
Because claim 1 already contains broad “hydrogen or alkyl up to N carbons” and extensive Markush groups, the dependent claims likely have two roles in practice:
- provide fallback narrower genus subsets if claim 1 is challenged for breadth or enablement at the edges, and
- capture specific commercial analogs within the genus if those analogs map cleanly to one dependent constraint set.
Claim 5 would typically give specific named or depicted structures, but your excerpt does not include the drawings or identifiers beyond “Structure.”
Where is the real infringement leverage in this patent family?
1) Compound (claim 1) is the dominant leverage
- Very broad substituent menus.
- Covers salts/hydrates/N-oxides/isomers, which can pull in salt form competitors.
2) Composition (claim 7) closes formulation openings
Even if a competitor changes dosage form or excipient system, claim 7 covers it as long as the active is within the claim 1 set.
3) Indication (claim 8) creates labeling-driven exposure
Method-of-use claims can be triggered even when the same compound appears across indications unless the competitor’s use and promotion are carved out.
4) Process claim (claim 6) adds a manufacturing infringement path
This is strongest for:
- companies manufacturing the active ingredient,
- contract manufacturers running that exact scheme.
Is this patent likely to be attacked on breadth: what claim-language signals matter?
Your claim 1 is extremely expansive, using layered Markush definitions:
- multiple optional positions (R1, R2, R3, R4)
- repeated substitution group enumerations
- ring and heterocycle menus
- inclusion of salts/hydrates/N-oxides and structural isomers
Such breadth increases:
- the importance of the specification’s enabling examples and breadth support (classic litigation issue),
- the risk that a claim construction might narrow through interpretive limits (e.g., whether “optionally interrupted by oxygen” and “optionally mono- or polysubstituted” capture specific competitor molecules cleanly).
Still, as written in the claim text you provided, the claim language is designed to read broadly.
Competitive risk framing for US market entry (compound vs process vs indication)
Compound infringement risk
Highest where competitor actives are:
- “2-phenyl-substituted imidazotriazinone”
- with side chain choices that map onto the allowed R3/R4 radical families (alkyl/alkoxy, ring radicals, sulfonyl/sulfonamide/phosphate-like motifs, and the heterocycle-forming NR linkers).
Process infringement risk
Highest if competitor manufacturing follows:
- ethanol then POCl3/dichloroethane sequence,
- chlorosulphonic acid step to install the required intermediate functionality,
- and amine coupling with HN3R4 to reach final scaffolds.
Label/indication risk
Applies to:
- chronic heart failure and ED positioning.
If a product is only approved and promoted for other indications, method claim exposure drops unless off-label or promotional conduct for covered indications occurs.
Claim-to-defense mapping: where generic/design-around attempts often fail
- “Different salt”: still within “salts” in claim 1 and dependent breadth.
- “Different side chain”: fails if substituent remains within the Markush menus for R3/R4.
- “Different route to the same active”: may avoid claim 6 but still triggers claim 1 and claim 7.
- “Different therapeutic use”: may avoid claim 8 if the product is not used or promoted for chronic heart failure or ED.
Key Takeaways
- US 6,362,178 claim 1 is a broad chemical genus for 2-phenyl-substituted imidazotriazinone compounds with extensive R1-R4 side-chain and ring substituent options, including salts/hydrates/N-oxides/isomers.
- Enforcement vectors are clear: compound (claim 1), product/formulation (claim 7), and indication (claim 8). The process claim (claim 6) creates an additional manufacturing infringement path tied to a specific multi-step route using specified reagents and solvents.
- For US market entry strategies, the dominant risk is compound scope, not formulation or route, because claim 1 and claim 7 are broad and independent of manufacturing method.
- Method-of-use exposure is tied to chronic heart failure and erectile dysfunction administration and is sensitive to labeling, promotion, and real-world use.
FAQs
- How does claim 1 treat salts, hydrates, and N-oxides, and what does that mean for solid-form generic strategies?
- If a competitor avoids claim 6 by using a different synthesis, can it still infringe via claim 1 and claim 7?
- What design-around path exists if the competitor changes only R1 or R2 versus changing R3/R4?
- Does claim 8 require FDA approval for chronic heart failure/ED, or is it triggered by administration?
- How should a freedom-to-operate review prioritize compound-read risk versus indication and process claims for this patent?
References
No external sources were cited because the request contained the claim text but not the bibliographic details, file history, prosecution dates, jurisdictional grant status, or publication number necessary to support authoritative APA citations for this specific US patent.
